Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

2.

Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients.

Luo G, Jin K, Guo M, Cheng H, Liu Z, Xiao Z, Lu Y, Long J, Liu L, Xu J, Liu C, Gao Y, Ni Q, Yu X.

Oncol Lett. 2017 Feb;13(2):881-886. doi: 10.3892/ol.2016.5501. Epub 2016 Dec 14.

3.

Primary pancreatic lymphoma: two case reports and a literature review.

Yu L, Chen Y, Xing L.

Onco Targets Ther. 2017 Mar 20;10:1687-1694. doi: 10.2147/OTT.S121521. eCollection 2017.

4.

Focused update on Gastrointestinal (GI) Oncology from ASCO 2016.

Paluri RK.

Indian J Med Paediatr Oncol. 2016 Oct-Dec;37(4):314-318. doi: 10.4103/0971-5851.195753. No abstract available.

5.

Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer.

Hwang HK, Kim HI, Kim SH, Choi J, Kang CM, Kim KS, Lee WJ.

Oncol Lett. 2016 Dec;12(6):4477-4484. doi: 10.3892/ol.2016.5252. Epub 2016 Oct 13.

6.

Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea.

Jang WI, Kim MS, Kang SH, Jo AJ, Kim YJ, Tchoe HJ, Park CM, Kim HJ, Choi JA, Choi HJ, Paik EK, Seo YS, Yoo HJ, Kang JK, Han CJ, Kim YJ, Kim SB, Ko MJ.

Oncotarget. 2017 Feb 7;8(6):9587-9596. doi: 10.18632/oncotarget.14525.

7.

Preoperative predictors for early recurrence of resectable pancreatic cancer.

Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B, Hirakawa K, Ohira M.

World J Surg Oncol. 2017 Jan 10;15(1):16. doi: 10.1186/s12957-016-1078-z.

8.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A.

Clin Transl Oncol. 2017 Jun;19(6):667-681. doi: 10.1007/s12094-016-1594-x. Epub 2016 Dec 19.

9.

Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?

Martinez-Useros J, Garcia-Foncillas J.

Biomed Res Int. 2016;2016:4873089. Epub 2016 Sep 1. Review.

10.

Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Petrushnko W, Gundara JS, De Reuver PR, O'Grady G, Samra JS, Mittal A.

HPB (Oxford). 2016 Aug;18(8):652-63. doi: 10.1016/j.hpb.2016.05.004. Epub 2016 Jul 14. Review.

11.

Risk and Surveillance of Cancers in Primary Biliary Tract Disease.

Hrad V, Abebe Y, Ali SH, Velgersdyk J, Al Hallak M, Imam M.

Gastroenterol Res Pract. 2016;2016:3432640. doi: 10.1155/2016/3432640. Epub 2016 Jun 19. Review.

12.

Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have.

Herreros-Villanueva M, Bujanda L.

Ann Transl Med. 2016 Apr;4(7):134. doi: 10.21037/atm.2016.03.44. Review.

13.

ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.

Fukushima H, Yasumoto M, Ogasawara S, Akiba J, Kitasato Y, Nakayama M, Naito Y, Ishida Y, Okabe Y, Yasunaga M, Horiuchi H, Sakamoto E, Itadani H, Mizuarai S, Oie S, Yano H.

Mol Cancer. 2016 May 4;15(1):32. doi: 10.1186/s12943-016-0516-4.

14.

CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.

Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA, Donahue TR.

J Gastrointest Surg. 2016 Jul;20(7):1331-42. doi: 10.1007/s11605-016-3149-4. Epub 2016 Apr 25.

PMID:
27114246
15.

Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology.

Abrams MJ, Rakszawski K, Vasekar M, Passero F, Abbas A, Jia Y, Saif MW.

Therap Adv Gastroenterol. 2016 Mar;9(2):141-51. doi: 10.1177/1756283X15622601. No abstract available.

16.

Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Pugalenthi A, Protic M, Gonen M, Kingham TP, Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ.

J Surg Oncol. 2016 Feb;113(2):188-93. doi: 10.1002/jso.24125. Epub 2015 Dec 18.

17.

Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management.

Hartwig W, Büchler MW.

Gastrointest Tumors. 2013 Sep;1(1):41-52. doi: 10.1159/000354992. Epub 2013 Sep 12. Review.

18.

Molecular detection of pancreatic neoplasia: Current status and future promise.

Majumder S, Chari ST, Ahlquist DA.

World J Gastroenterol. 2015 Oct 28;21(40):11387-95. doi: 10.3748/wjg.v21.i40.11387. Review.

19.

Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new.

Boyle J, Czito B, Willett C, Palta M.

J Gastrointest Oncol. 2015 Aug;6(4):436-44. doi: 10.3978/j.issn.2078-6891.2015.014. Review.

20.

Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas.

Ben-Josef E, George A, Regine WF, Abrams R, Morgan M, Thomas D, Schaefer PL, DiPetrillo TA, Fromm M, Small W Jr, Narayan S, Winter K, Griffith KA, Guha C, Williams TM.

Clin Cancer Res. 2015 Dec 15;21(24):5612-8. doi: 10.1158/1078-0432.CCR-15-0789. Epub 2015 Aug 3.

Supplemental Content

Support Center